Our Take
A positive CHMP opinion is a regulatory step, not a market win; the real test is whether EC approval in weeks translates to meaningful uptake against entrenched BTK inhibitors already in the clinic.
Why it matters
Oncology practitioners and hospital formulary committees need to track which new CLL agents are gaining regulatory clearance in Europe and the US, since treatment sequencing decisions for newly diagnosed patients depend on approved options and real-world efficacy data. Lilly's submission strategy reveals how aggressively it is positioning pirtobrutinib across all lines, not just salvage.
Do this week
Oncology medical directors: request efficacy and tolerability summaries from the BRUIN CLL-313 and CLL-314 trial publications before the EC decision so you can draft formulary policy updates ahead of any EU approval.
EMA committee backs pirtobrutinib for all CLL treatment lines
Eli Lilly announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia in adults. The recommendation covers all lines of therapy, including patients who have not yet received a Bruton tyrosine kinase (BTK) inhibitor. The application now moves to the European Commission, which is expected to issue a final decision within one to two months.
The CHMP opinion rests on data from two Phase III trials: BRUIN CLL-313, a 282-patient global study comparing pirtobrutinib to chemoimmunotherapy in patients without 17p deletions, and BRUIN CLL-314, a 662-patient trial pitting pirtobrutinib against Imbruvica (ibrutinib) in treatment-naïve and BTK inhibitor-naïve patients. Both trials measured efficacy and safety across multiple endpoints.
Pirtobrutinib is a highly selective, non-covalent BTK inhibitor approved by the US FDA and dosed once daily at 200 mg. Lilly has also filed with the US Food and Drug Administration, with a decision expected in the second half of 2026.
Another BTK inhibitor in a crowded CLL market
Chronic lymphocytic leukaemia remains one of the most common adult leukaemias. Treatment intensity and sequence have shifted in recent years as newer agents have entered the market, meaning fewer patients receive multiple lines of therapy over their lifetime. This makes early-line treatment choices material.
Pirtobrutinib enters a landscape already anchored by ibrutinib (Imbruvica) and other established BTK inhibitors. The key differentiator Lilly is claiming is selectivity and the potential to treat patients across all therapy lines, including those who may have developed resistance or intolerance to prior BTK inhibitors. However, the efficacy advantage over ibrutinib in the BRUIN CLL-314 population remains to be scrutinized in peer-reviewed publication and real-world practice.
EC approval would mark the second major regulatory gate (after FDA approval) and signal sufficient clinical confidence to place the drug on European hospital formularies. Adoption will depend on cost, reimbursement, and whether trial results translate to clinic practice.
What oncology teams should do before EU approval
Formulary committees and medical oncologists should obtain the full trial protocols and efficacy/safety data from BRUIN CLL-313 and CLL-314 before or immediately after the EC decision. Compare progression-free survival, overall survival, and adverse event rates head-to-head against ibrutinib and other BTK inhibitors on your institution's current CLL regimen list. Request health economics data on cost per response and long-term cost-effectiveness if pirtobrutinib will compete for first-line or second-line budgets. Clarify with Lilly whether the EC approval covers all lines or carries restrictions that might affect your early-treatment protocols.